Arcus Biosciences, Inc.
RCUS
$22.43
$0.220.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -353.00M | -341.00M | -298.00M | -391.00M | -283.00M |
| Total Depreciation and Amortization | 10.00M | 10.00M | 10.00M | 10.00M | 10.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.00M | 56.00M | 56.00M | 59.00M | 81.00M |
| Change in Net Operating Assets | -194.00M | -187.00M | -107.00M | 22.00M | 22.00M |
| Cash from Operations | -482.00M | -462.00M | -339.00M | -300.00M | -170.00M |
| Capital Expenditure | -2.00M | -2.00M | -3.00M | -3.00M | -6.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 68.00M | 301.00M | 194.00M | 120.00M | -78.00M |
| Cash from Investing | 66.00M | 299.00M | 191.00M | 117.00M | -84.00M |
| Total Debt Issued | 49.00M | 49.00M | 96.00M | 47.00M | 47.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 439.00M | 156.00M | 150.00M | 150.00M | 237.00M |
| Repurchase of Common Stock | -- | -5.00M | -6.00M | -7.00M | -7.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 488.00M | 200.00M | 240.00M | 190.00M | 277.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.00M | 37.00M | 92.00M | 7.00M | 23.00M |